impacts. We think the company's growth by acquisition strategy, such as its recent $5.2 billion purchase of NPSPharmaceuticals , reinforces Shire's narrow economic moat, as the deal adds new drugs to its growing rare disease portfolio and leverages

We anticipate increasing Shire’s FVE by about 5% following its agreement to acquire NPSPharmaceuticals for $5.2 billion in cash (or $46 per share). We think it reinforces Shire's narrow economic moat, as the deal will add

Pharmaceuticals International, Inc. (U.S. Shares) (2.19%), AstraZeneca PLC (ADR) (1.78%) and NPSPharmaceuticals , Inc. (1.74%). There are no assurances that any Janus portfolio currently holds these securities or other

We are no longer providing equity research on NPS Pharma NPSP . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.